Back HCV Populations Injection Drug Users

CROI 2014: Monkey Studies Confirm Validity of Injectable PrEP

Two studies in monkeys of an injectable formulation of the third-generation integrase inhibitor drug GSK1265744 (or GSK744LA, where LA stands for "long-acting") have strengthened the evidence that it may work as pre-exposure prophylaxis (PrEP) in humans, researchers reported at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston. A Phase 2 study in humans will be starting soon.

alt

Read more:

CROI 2014: Long-acting GSK744 Protects Monkeys against HIV-like Virus [VIDEO]

A long-acting injectable formulation of the next-generation integrase inhibitor GSK1265744 protected monkeys from infection via vaginal or anal exposure to a hybrid human-simian virus, according to 2 studies presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston. These promising findings suggest this may be a future approach to pre-exposure prophylaxis (PrEP).

alt

Read more:

CROI 2014: HIV in People Who Use Drugs [VIDEO]

Despite ample evidence that syringe exchange and opiate substitution therapy work to help prevent transmission of HIV and viral hepatitis, access remains "woefully inadequate" in most parts of the world, Adeeba Kamarulzaman from the University of Malaya said during her plenary talk at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston.

alt

Read more: